1 / 32

ENTEROBACTERIACEAE

ENTEROBACTERIACEAE. Dr. Abdulaziz Alkhattaf. coliforms. Non-spore forming, gram negative bacilli. Facultative anaerobic. Catalase + ve ; Oxidase – ve . Motility ±; some are capsulated . Widely dispersed in nature, yet was found to inhabit the intestine of mammalians.

rob
Download Presentation

ENTEROBACTERIACEAE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ENTEROBACTERIACEAE Dr. Abdulaziz Alkhattaf

  2. coliforms • Non-spore forming, gram negative bacilli. • Facultative anaerobic. • Catalase +ve; Oxidase–ve. • Motility ±; some are capsulated. • Widely dispersed in nature, yet was found to inhabit the intestine of mammalians. • Grow well in ordinary media (blood agar, Mc-conkey agar) aerobically or facultative anaerobic.

  3. Identification • Lactose fermentation: • McConkey agar contains lactose and pH indicator + pink colonies. • CLED agar changes from blue-green to yellow colonies. • Biochemical tests: (a)- Reduce nitrate to nitrite. (b)- Ferment glucose with acid (sometimes gas production). (c)- The use of API 20E biochemical kit tests.

  4. Identification tools used in the lab

  5. Identification of coliforms • Serological tests: • Based on the somatic (O) antigen and the flagellar antigen (H) for the identification of Salmonella and Shigella species. • Bacteriophage typing (using viruses to identify bacteria). • Bacteriocine typing (pigments produced by bacteria). • Plasmid analysis (extra-chromosomal DNA). • Polypeptide analysis (polyacrylamide gel electrophoresis).

  6. Antigenic structure • Enterobacteria possess variety of heterogeneous antigens: • Somatic/cell wall (O) • Flagella (H) • Capsular (K)

  7. Pathogenicity • Virulence Factors: • Endotoxin: Lipopolysaccharide Lipid A: toxin Polysaccharide: antigenic • Capsule –antiphagocytic. • Pili -for attachment ( K88 of E.coli→dirrhoea/infant pigs) • Enterotoxins→ e.gE.coli causing diarrhoea.

  8. Pathogenicity • Diseases: • Intestinal Salmonella }Primary • Shigella } intestinal Pathogens. • E.coli:some strains are intestinal • Pathogens. • Extra-intestinal • UTI –Coliforms contribute up to 80% UTI. • Wound infections/ post operative. • Respiratory tract infection. • Septicaemia. • Meningitis→neonates (E.coli) /or with trauma /surgery

  9. Antibiotic sensitivity • Enterobacteria are resistant to multiple antibiotics. • In vitro sensitivity testing is required to monitor the trend and to assess based on case by case. • The most common antibiotic used are: • Ampicillin/ amoxycillin and mezlocillin. • Aminoglycosides. • Trimethoprim. • Chloramphenicol. • Ciprofloxacin. • Cephalosporins (2nd,3rd generations) • Nitrofurantoin, Nalidixic acid/ UTI only.

  10. Escherichia coli • Serology of E.coli: • According to the cell wall (O antigen) over 160 types recognized. • According to the flagellar (H antigen) 55 types. • Making over 8000 possible O-H seotypes. • Some E.coli types are capsulated

  11. Pathogenicity of E.coli • Intestinal:

  12. Pathogenicity of E.coli • Extra-intestinal • Urinary tract infection (UTI)/ causes 80% of UTI in pregnant females. • Wound infection/ Surgery of lower intestinal tract. • Peritonitis. • Septicemia. • Neonatal meningitis.

  13. KLEBSIELLA l ENTEROBACTER/ SERRATIA • Widely spread in the environment/ in the intestine flora of man and animals. • Survive well in moist environments in hospitals. • Opportunistic pathogens → chances of infection are increased in long term hospitalization, ICU. • Grow well on all media /producing large and mucoid colonies (capsule). • Β-lactamases producing/ resistant to ampicillin,1st and 2nd generation of cephalosporins→ therefore we resort to using Aminoglycosides.

  14. Pathogenicity • Urinary tract infection (chronic, complicated infections). • Wounds, skin lesions and respiratory infections in hospitalised patients. • Septicemia. • Abscesses, endocarditis, chronic nasal and oropharyngeal sepsis. • Meningitis (neonates).

  15. PROTEUS /MORGANELLA / PROVIDENCIA • Habitat: Human and animal intestine//soil/ water. • Isolation: Grow well on ordinary media in a swarming type, which cover the plate. • Identification: Swarming, and all species produce a potent urease enzyme. • phage, bacteriocine and serotyping schemes have been developed for identification there species.

  16. Pathogenesis • Urinary tract infection / urea is split by the Proteus urease to produce ammonia→alkaline urinary pH. • Urease-producing organisms (proteus) may provoke the formation of calculi (stones) in urinary tract. • Ear ,wound and burn infections (mixed infection). • Septicaemia and brain abcesses.

  17. PSEUDOMONAS • Gram Negative Bacilli; non-fermentative strictly aerobic, motile and oxidase positive. • Pseudomonas species commonly inhibit soil, water and are widely spread. Can use variety of carbon and nitrogen sources. • Difficult to eradicate / especially in hospital wards, operating theatres and medical equipments (respiratory ventilators) being resistant to many disinfectants. • clinical isolates produce a characteristic green or blue-green pigment called Pyocyanin. Also produce Pyoverdin(fluorescein) a yellow-green pigment↔fluoresces under UV light .

  18. Pathogenesis • Ps.aeruginosa is an important opportunistic pathogen. • causing infection in immunocompromised patients / burns, HIV,cancer and cystic fibrosis patients. • pseudomonas enters blood stream causing sepsis with 50% mortality rate. • spread to skin causing black necrotic lesions (ecthymagangrenosum). • Severe external otitis (malignant otitisexterna). • other skin lesions (folliculitis)↔ inadequate chlorinated swimming pool users. • Corneal infections↔ contact lens users.

  19. Treatment • Psedomonas is resistant to many antibiotics /e.g penicillin, ampicillin, tetracycline, most cephalosporins. • Psedomonas infections were usually treated with polymyxins, now stopped for its high toxicity. • Antipseudomonalβ-lactam compounds such as zlocillin, ticarcillin, imipenem and ceftazidime are commonly used. • Aminoglycosides such as gentamicin and tobramycin are also used and some times with combination β-lactams. • Fluoroquinolones (ciprofloxacin) can be given orally.

  20. Epidemiology • Species have the ability to multiply on moist equipments (humidifiers) in hospital wards, bathrooms& kitchens. • Resistant to many disinfectants and antiseptics. • Can contaminate pharmaceutical preparations and may cause ophthalmitis to contact lenses users. • Important cause of nosocomial infections 10-30% of hospital-acquired infections. • Airborne pseudomonas is hazardous to burned and ICU patients. • Ear infection and irritating folliculitis (jacuzzi rash) occur due to poorly maintained swimming pools or jacuzzis.

  21. Pseudomonal control • Prevention is easier than cure: • Immunocompromised and patient with high risk of acquiring Ps. aeruginosa should not be admitted to a ward with cases of such infection are present. • Therapeutic substances must be free from Ps especially multi-dose ointments, creams or eye drops. • Using typing system to identify cross-infection of one strain (epidemic strains).

  22. Acinetobacter • Gram negative coccobacilli resemble Enterobacteriaceae in growth pattern and colonial morphology. • Incapable of fermenting carbohydrates or reduce nitrates. • Appear frequently as skin and respiratory colonizers. • Frequently contaminate wet objects including soaps and disinfectant solutions. • Pneumonia, urinary tract and soft tissue are the most common infections

  23. Nosocomial respiratory infections are traced to contaminated inhalation therapy equipments whereas bacteremia to infected intravenous catheters. • Due to frequent resistance to penicillins, cephalosprins and some aminoglycosides treatment is difficult and required prior sensitivity testing.

  24. Moraxella • Gram negative coccobacilli in pairs. • Fastidious growth (required enriched media-chocolate agar). • Due to similarity in morphology and positive oxidase reaction Moraxella is some times confused with Neisseria. • Causes otitis media, sinusitis and lower respiratory infection.

  25. Burkholderiapseudomallei • Free living saprophyte that causes melioidosis, a devastating tropical infection of animal and humans that is endemic in eastern Asia and north Australia. • Laboratory-acquired infection is a serious risk; the species is included in hazard group 3 (together with plague).

  26. Melioidosis: • Human infection is mainly acquired cutaneously through skin abrasions or by inhalation of contaminated particles. • Clinical manifestation range from a sub-clinical infection, diagnosed by the presence of specific antibodies, to a benign pulmonary infection that may resemble tuberculosis or septicemia with mortality rate of 80-90%. • In north eastern Thailand, B.pseudomallieis responsible for 20% of all community acquired septicemia.

  27. Early diagnosis and appropriate antibiotic therapy are key factors in the successful management of melioidosis. • Organism may be isolated from sputum, urine, pus or blood (gram –ve bacilli). • ELISA is used for detection of IgGanfIgMantibodiy to B.pseudomallieas well as indirect haemagglutination test.

  28. Treatment • Combination of tetracycline and chloramphenicol for long period of time, have been widely used. • The ability of B.pseudomallie to survive and multiply in phagocytic macrophages may explain the difficulty to treat the disease. • Antibiotics that are effective against the organism in vitro are not successful in vivo unless with prolong period of treatment. • Ceftazidime is both effective in vitro and in vivo.

  29. Burkholderiacepacia • Major opportunistic cause of respiratory infection in patients with chronic granulomatous (cystic fibrosis) disease. • The organism is multi-resistance to many antibiotics and transport by social contact. • Cepacia syndrome, an acute fatal necrotizing pneumonia, some times accompanied by bacteraemia is a risk with B.cepacia. • For treatment of B.cepaciaceftazidime or cabapenem, meropenem.

  30. Eikenellacorrodens • Commensal of mucosal surface may cause range of infections such as endocarditis, meningitis, pneumonia and infections of wounds and various soft tissues.

  31. Flavobacteriummeningosepticum • Meningitis with F.meningosepticum is responsible for high mortality in epidemic outbreaks. • Is a saprophyte that could cause opportunistic nosocomial infections in infants.

More Related